QUEENSBURY, N.Y.--(BUSINESS WIRE)--July 14, 2004--AngioDynamics, Inc., (Nasdaq:ANGO) today announced that the underwriters of its initial public offering of May 27, 2004 have exercised their over-allotment option in full to purchase an additional 292,500 shares of common stock at the public offering price of $11.00 per share.

RBC Capital Markets served as lead manager and sole book-running manager, and Adams, Harkness & Hill acted as co-manager.

A registration statement relating to these securities was declared effective by the Securities and Exchange Commission on May 26, 2004. This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

About AngioDynamics

AngioDynamics, Inc. (www.angiodynamics.com) designs, develops, manufactures and markets innovative medical devices used in minimally invasive, image-guided procedures to treat peripheral vascular disease. It offers a broad line of therapeutic and diagnostic devices that enable interventional physicians, such as interventional radiologists, vascular surgeons and others, to treat peripheral vascular diseases and other non-coronary diseases. AngioDynamics' diversified product line includes angiographic catheters, hemodialysis catheters, PTA dilation catheters, thrombolytic products, image-guided vascular access products, endovascular laser venous system products, as well as drainage products. AngioDynamics is a majority-owned subsidiary of E-Z-EM, Inc. (AMEX:EZM), a leading manufacturer of contrast agents for gastrointestinal radiology.

    CONTACT: AngioDynamics, Inc.
             Lisa Donegan, 800-772-6446 x370
             http://www.angiodynamics.com
             or
             Investor Relations Contacts:
             Lippert/Heilshorn & Associates, Inc.
             Kim Sutton Golodetz, 212-838-3777
             kgolodetz@lhai.com
             Bruce Voss, 310-691-7100
             bvoss@lhai.com

    SOURCE: AngioDynamics, Inc.